文献速递乳腺癌

PEARLY研究:早期三阴性乳腺癌在蒽环序贯紫杉类基础上加卡铂改善EFS

A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.
PubMed 文献 · Ann Oncol · 2026-05-30

PEARLY是多中心随机III期试验,纳入868例II-III期三阴性乳腺癌患者,比较蒽环序贯紫杉类(对照)与在紫杉类阶段加卡铂的疗效。中位随访57.2个月,卡铂组无事件生存(EFS)显著改善(HR 0.67,95%CI 0.49-0.92,P=0.012),5年EFS由75.1%升至82.3%。OS、IDFS、DRFS呈同向趋势但未达统计学显著,≥3级不良事件以血液学毒性为主更常见。

要点

  • 卡铂组EFS显著优于对照,5年EFS绝对提高7.2%
  • OS、IDFS、DRFS呈有利于卡铂的趋势但未达统计学显著
  • ≥3级不良事件卡铂组74.7%高于对照56.7%,主要为血液学毒性

核心结论

  • 在蒽环序贯紫杉类方案基础上加入卡铂可显著改善早期三阴性乳腺癌的无事件生存。

研究设计与样本

  • 多中心、随机、III期试验,2016年1月至2020年6月韩国22家机构共随机868例II或III期三阴性乳腺癌患者,分对照臂与卡铂臂。
  • 主要终点为无事件生存(EFS),次要终点包括总生存(OS)、侵袭性疾病无生存(IDFS)、远处无复发生存(DRFS)、pCR率与安全性。

主要发现

  • 中位随访57.2个月,卡铂组EFS显著优于对照(HR 0.67,95%CI 0.49-0.92,P=0.012)。
  • 5年EFS率由75.1%提高至82.3%,绝对差异7.2%。
  • OS、IDFS、DRFS呈方向一致地有利于卡铂臂的趋势,但均未达统计学显著。
  • ≥3级治疗相关不良事件卡铂臂74.7%、对照臂56.7%,主要由血液学毒性驱动。
  • 未观察到有临床意义的生活质量恶化。

关键数值与推荐

  • EFS:HR 0.67(95%CI 0.49-0.92),P=0.012。
  • 5年EFS率:对照臂75.1%,卡铂臂82.3%,绝对差异7.2%。
  • ≥3级治疗相关不良事件:卡铂臂74.7%,对照臂56.7%。

临床怎么用

  • 对II-III期早期三阴性乳腺癌,可考虑在蒽环序贯紫杉类方案中加入卡铂以改善EFS。
  • 加卡铂需重点监测血液学毒性,≥3级不良事件发生率较高。

局限性

  • OS、IDFS、DRFS未达统计学显著,仅为方向性趋势。
  • 随访时间仍为中位57.2个月,长期生存获益待进一步随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum agents have been shown to increase pathologic complete response (pCR) rates when added to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). The PEARLY multicenter, randomized, phase III trial investigated the efficacy and safety of adding carboplatin to standard anthracycline-based and taxane chemotherapy for patients with early-stage TNBC in the neoadjuvant or adjuvant settings. PATIENTS AND METHODS: Patients with stage II or III TNBC were enrolled. Patients received either standard therapy with doxorubicin and cyclophosphamide followed by a taxane (control arm) or carboplatin in addition to a taxane following doxorubicin and cyclophosphamide (carboplatin arm). The primary endpoint was event-free survival (EFS). Secondary endpoints included overall survival (OS), invasive disease-free survival (IDFS), distant recurrence-free survival (DRFS), pCR rate, and safety. RESULTS: Between January 2016 and June 2020, 868 patients across 22 institutions in the Republic of Korea were randomly assigned to either the control arm or carboplatin arm. At a median follow-up of 57.2 months, carboplatin significantly improved EFS compared with the control [hazard ratio 0.67, 95% confidence interval (CI) 0.49-0.92, P = 0.012]. The 5-year EFS rates increased from 75.1% to 82.3% with an absolute 7.2% difference. Secondary endpoints, including OS, IDFS, and DRFS, showed directionally consistent trends favoring the carboplatin arm, though none reached statistical significance. Grade 3 or higher treatment-related adverse event rates were more frequent in the carboplatin arm (74.7%) than in the control arm (56.7%), driven primarily by hematologic toxicity. CONCLUSION: The addition of carboplatin to doxorubicin and cyclophosphamide followed by taxane therapy significantly improved EFS in patients with early-stage TNBC. Despite a higher incidence of grade ≥3 adverse events in the carboplatin arm, no clinically meaningful deterioration in quality of life was observed, supporting a favorable risk-benefit profile for carboplatin incorporation into early TNBC treatment.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kim GM, Jung KH, Jeung HC, et al. A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial. Ann Oncol. 2026. PMID: 42218963. doi:10.1016/j.annonc.2026.05.703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。